Effect of Pycnogenol® on attention-deficit hyperactivity disorder (ADHD): Study protocol for a randomised controlled trial

Trials

Volumn 18, Issue 1, 2017, Pages

  Verlaet, Annelies A J ^a   Ceulemans, Berten ^b   Verhelst, Helene ^c   Van West, Dirk ^d   De Bruyne, Tess ^a   Pieters, Luc ^a   Savelkoul, Huub F J ^e   Hermans, Nina ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d University Child and Adolescent Psychiatry Antwerp   (Belgium)

^e WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

ADD; ADHD; Antioxidant; Behaviour; Catecholamines; Immunity; Oxidative stress; Polyphenols; Pycnogenol

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ANTIBODY; CATECHOLAMINE; CYTOKINE; GLUTATHIONE; LIPID; MALONALDEHYDE; METHYLPHENIDATE; NEUROPEPTIDE Y; PLACEBO; PYCNOGENOL; VITAMIN; ZINC; ANTIOXIDANT; BIOLOGICAL MARKER; CENTRAL STIMULANT AGENT; FLAVONOID; IMMUNOLOGICAL ADJUVANT; PYCNOGENOLS;

ADVERSE OUTCOME; ARTICLE; ATTENTION DEFICIT DISORDER; ATTENTION DEFICIT DISORDER RATING SCALE; CHILD; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EMOTION ASSESSMENT; ENZYME ACTIVITY; FECES ANALYSIS; GENE EXPRESSION; HUMAN; IMMUNITY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MENTAL DISEASE ASSESSMENT; MULTICENTER STUDY; OXIDATIVE STRESS; PHASE 3 CLINICAL TRIAL; PHYSICAL COMPLAINTS QUESTIONNAIRE; PRACTICE GUIDELINE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SOCIAL EMOTIONAL QUESTIONNAIRE; BELGIUM; BLOOD; CHILD BEHAVIOR; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECTS; FACE; FEEDING BEHAVIOR; FEMALE; IMMUNOLOGY; MALE; METABOLISM; METHODOLOGY; MICROBIOLOGY; PSYCHOLOGY; TIME FACTOR; TREATMENT OUTCOME; URINE;

ADJUVANTS, IMMUNOLOGIC; ANTIOXIDANTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BELGIUM; BIOMARKERS; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD BEHAVIOR; CLINICAL PROTOCOLS; CYTOKINES; DOUBLE-BLIND METHOD; FACE; FEEDING BEHAVIOR; FEMALE; FLAVONOIDS; HUMANS; MALE; METHYLPHENIDATE; OXIDATIVE STRESS; RESEARCH DESIGN; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME;

EID: 85016507161     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-017-1879-6     Document Type: Article

References (63)

1. Pelham WE, Foster EM, Robb JA. The economic impact of attention-deficit/hyperactivity disorder in children and adolescents. J Pediatr Psychol. 2007;32(6):711-27.
2. Polanczyk GV, et al. ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. Int J Epidemiol. 2014;43(2):434-42.
3. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet. 2005;366:237-48.
4. Antshel KM, et al. Advances in understanding and treating ADHD. BMC Med. 2011;9:72.
5. Claes S, et al. Het toenemend gebruik van psychofarmaca. Visietekst werkgroep Metaforum Leuven, Katholieke Universiteit Leuven. 2010.
6. Schachter HM, et al. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis CMAJ. 2011;165(11):1475-88.
7. Steer CR, Suppl I. Managing attention deficit/hyperactivity disorder: unmet needs and future directions. Arch Dis Child. 2005;90:i19-25.
8. Storebø OJ, et al. Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. BMJ. 2015;351:h5203.
9. Ceylan M, et al. Changes in oxidative stress and cellular immunity serum markers in attention-deficit/hyperactivity disorder. Psychiatry Clin Neurosci. 2012;66:220-6.
10. Pelsser LMJ, Buitelaar JK, Savelkoul HFJ. ADHD as a (non) allergic hypersensitivity disorder: a hypothesis. Pediatr Allergy Immunol. 2009;20(2):107-12.
11. Ceylan M, et al. Oxidative imbalance in child and adolescent patients with attention-deficit/hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(8):1491-4.
12. El Adham EK, Hassan AI, El Aziz El-Mahdy AA. Nutritional and metabolic disturbances in attention deficit hyperactivity disease. Res J Med Med Sci. 2011;6(1):10-6.
13. Ross BM, et al. Increased levels of ethane, a non-invasive marker of n-3 fatty acid oxidation, in breath of children with attention deficit hyperactivity disorder. Nutr Neurosci. 2003;6(5):277-81.
14. Kawatani M, Tsukahara H, Mayumi M. Evaluation of oxidative stress status in children with pervasive developmental disorder and attention deficit hyperactivity disorder using urinary-specific biomarkers. Redox Rep. 2011;16(1):45-6.
15. Güngör S, et al. The frequency of celiac disease in attention-deficit hyperactivity disorder. J Pediatr Gastroenterol Nutr. 2013;56(2):211-4.
16. Minter K, et al. Early childhood otitis media in relation to children's attention-related behavior in the first six years of life. Pediatrics. 2001;107:1037-42.
17. Schmitt J, Buske-Kirschbaum A, Roessner V. Is atopic disease a risk factor for attention-deficit/hyperactivity disorder? A systematic review. Allergy. 2010;65(12):1506-24.
18. Tsai SJ. Signal transducer and activator of transcription 6 (STAT6) and attention-deficit hyperactivity disorder: a speculative hypothesis. Med Hypoth. 2006;67(6):1341-3.
19. Furlano R, et al. Colonic CD8 and gamma delta T-cell infiltration with epithelial damage in children with autism. J Pediatr. 2001;138(3):366-72.
20. Noriega DB, Savelkoul HFJ. Immune dysregulation in autism spectrum disorder. Eur J Ped. 2014;173(1):33-43.
21. Verlaet AAJ, et al. Nutrition, immunological mechanisms and dietary immunomodulation in ADHD. Eur Child Adolesc Psychiatry. 2014;23(7):519-29.
22. Trebatická J, et al. Treatment of ADHD with French maritime pine bark extract. Pycnogenol Eur Child Adolesc Psychiatry. 2006;15:329-35.
23. D'Andrea G. Pycnogenol: a blend of procyanidins with multifaceted therapeutic applications? Fitoterapia. 2010;81:724-36.
24. Wilson D, et al. A randomized, double-blind, placebo-controlled exploratory study to evaluate the potential of Pycnogenol for improving allergic rhinitis symptoms. Phytother Res. 2010;24(8):1115-9.
25. Chovanová Z, et al. Effect of polyphenolic extract, Pycnogenol, on the level of 8-oxoguanine in children suffering from attention deficit/hyperactivity disorder. Free Radical Res. 2006;40:1003-10.
26. Dvořáková M, et al. The effect of polyphenolic extract from pine bark, Pycnogenol, on the level of glutathione in children suffering from attention deficit hyperactivity disorder (ADHD). Redox Rep. 2006;11:163-72.
27. Tenenbaum S, et al. An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). J Atten Disord. 2002;6:49-60.
28. Greenblatt J. Nutritional supplements in ADHD. J Am Acad Child Adolesc Psychiatry. 1999;38:1209-10.
29. Heimann SW. Pycnogenol for ADHD? J Am Acad Child Adolesc Psychiatry. 1999;38:357-8.
30. Jennings CG, et al. Does offering an incentive payment improve recruitment to clinical trials and increase the proportion of socially deprived and elderly participants? Trials. 2015;16:80.
31. Kerkhoff LA, et al. Trends in consent for clinical trials in cardiovascular disease. J Am Heart Assoc. 2016;5(6):e003582.
32. Buitelaar JK, Montgomery SA, van Zwieten-Boot BJ. Attention deficit hyperactivity disorder: guidelines for investigating efficacy of pharmacological intervention. Eur Neuropsychopharmacol. 2003;13:297-304.
33. TestWeb. Sociaal-Emotionele Vragenlijst (SEV). 2013. Available from: http://testweb.bsl.nl/tests/sev/. Accessed date: 15 Dec 2016.
34. Pelsser LMJ, Buitelaar JK. Favourable effect of a standard elimination diet on the behaviour of young children with attention deficit-hyperactivity disorder (ADHD), a pilot study. Ned Tijdschr Geneesk. 2002;46(52):2543-7.
35. Pastore A, et al. Analysis of glutathione: implication in redox and detoxification. Clin Chim Acta. 2003;333(1):19-39.
36. Conaway HH, Henning P, Lerner UH. Vitamin a metabolism, action, and role in skeletal homeostasis. Endocr Rev. 2013;34:766-97.
37. Naguib Y, et al. Antioxidant activities of natural vitamin E formulations. J Nutr Sci Vitaminol. 2003;49:217-20.
38. Littarru GP, Tiano L. Bioenergetic and antioxidant properties of coenzyme Q10: recent developments. Mol Biotechnol. 2007;37:31-7.
39. Molyneux SL, et al. Coenzyme Q10: is there a clinical role and a case for measurement? Clin Biochem Rev. 2008;29(2):71-82.
40. Sezen H, et al. Increased oxidative stress in children with attention deficit hyperactivity disorder. Redox Rep. 2016;21(6):248-53.
41. Franceschi C, et al. Genes involved in immune response/inflammation, IGF1/insulin pathway and response to oxidative stress play a major role in the genetics of human longevity: the lesson of centenarians. Mech Ageing Dev. 2005;126(2):351-61.
42. Rahman I, Yang SR, Biswas SK. Current concepts of redox signaling in the lungs. Antioxid Redox Signal. 2006;8:681-9.
43. Whitehouse RC, et al. Zinc in plasma, neutrophils, lymphocytes, and erythrocytes as determined by flameless atomic absorption spectrophotometry. Clin Chem. 1982;28(3):475-80.
44. Aruoma OI. Free radicals, oxidative stress, and antioxidants in human health and disease. JAOCS. 1998;75:199-212.
45. Dalle-Donne I, et al. Biomarkers of oxidative damage in human disease. Clin Chem. 2006;52:601-23.
46. Furukawa T, Meydani SN, Blumberg JB. Reversal of age-associated decline in immune responsiveness by dietary glutathione supplementation in mice. Mech Ageing Dev. 1987;38(2):107-17.
47. Grimm T, et al. Inhibition of NF-ΚB activation and MMP-9 secretion by plasma of human volunteers after ingestion of maritime pine bark extract (Pycnogenol). J Inflam. 2006;3(1):1-6.
48. Booijink CC, et al. High temporal and inter-individual variation detected in the human ileal microbiota. Environ Microbiol. 2010;12(12):3213-27.
49. González TJB, et al. Study of the aminoglycoside subsistence phenotype of bacteria residing in the gut of humans and zoo animals. Front Microbiol. 2015;6:1-7.
50. Dvořáková M, et al. Urinary catecholamines in children with attention deficit hyperactivity disorder (ADHD): modulation by a polyphenolic extract from pine bark (Pycnogenol). Nutr Neurosci. 2007;10:151-7.
51. Ozcan O, et al. Plasma leptin, adiponectin, neuropeptide Y levels in drug naive children with ADHD. J Atten Disord. 2015 [Epub ahead of print].
52. de Vriese S, et al. The Belgian food consumption survey: aims, design and methods. Archives Public Health. 2005;63:1-16.
53. De Keyzer W, et al. Relative validity of a short qualitative food frequency questionnaire for use in food consumption surveys. Eur J Public Health. 2012;23(5):737-42.
54. Pelsser LMJ, et al. Effects of a restricted elimination diet on the behaviour of children with attention-deficit hyperactivity disorder (INCA study): a randomised controlled trial. Lancet. 2011;377:494-503.
55. Berek M, et al. Improved functionality, health related quality of life and decreased burden of disease in patients with ADHD treated with OROS® MPH: is treatment response different between children and adolescents? Child Adolesc Psych Ment Health. 2011;5(26):1-13.
56. Christensen E. Methodology of superiority vs. equivalence trials and non-inferiority trials. J Hepatol. 2007;46:947-54.
57. Piaggio G, et al. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA. 2006;295:1152-60.
58. Power TJ, et al. The predictive validity of parent and teacher reports of ADHD symptoms. J Psychopathol Behav Assess. 1998;20(1):57-81.
59. Tripp G, Schaughency EA, Clarke B. Parent and teacher rating scales in the evaluation of attention-deficit hyperactivity disorder: contribution to diagnosis and differential diagnosis in clinically referred children. J Dev Behav Pediatr. 2006;27(3):209-18.
60. Rohdewald PJ. Pycnogenol, French maritime pine bark extract. In: Coates PM, Blackman MR, Cragg GM, Levine M, Moss J, White JD, editors. Encyclopedia of Dietary Supplements. New York, Marcel Dekker, Inc.; 2005;545-53.
61. Belkaid Y, Hand T. Role of the microbiota in immunity and inflammation. Cell. 2014;157:121-41.
62. Cardona F, et al. Benefits of polyphenols on gut microbiota and implications in human health. J Nutr Biochem. 2013;24(8):1415-22.
63. Rohdewald P. A review of the French maritime pine bark extract (Pycnogenol), a herbal medication with a diverse clinical pharmacology. Int J Clin Pharmacol Ther. 2002;40(4):158-68.